Print

HVTN 702

A Pivotal Phase 2b/3 Multisite, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120/MF59 in Preventing HIV-1 Infection in Adults in South Africa

Trial Details:

III Ongoing
NIH, HVTN, South African Medical Research Council, Pox-Protein Public-Private Partnership, GSK, Sanofi, BMGF November 15, 2016
ALVAC-HIV-C (vCP2438), Bivalent Subtype C gp120/MF59 Canarypox Env gp120 C, gp41 B, gag B, protease B; Protein Env C
ALVAC-HIV-C (vCP2438) Viral Vector - Pox
Bivalent Subtype C gp120/MF59 Protein
MF59
South Africa 5,400
NCT02968849
https://www.clinicaltrials.gov/ct2/show/NCT02968849